RECRUITINGOBSERVATIONAL
Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes
Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes
About This Trial
Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.
Who May Be Eligible (Plain English)
Who May Qualify:
- Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
- Those with singleton pregnancy
- Those who did not conceive pregnancy with assisted reproductive treatment methods
- Those who do not have any pregestational diseases
- Those who do not have any uterine anomalies
Who Should NOT Join This Trial:
- Smokers
- Those who are in the high-risk group with the first trimester screening test
- Those with multiple pregnancies
- Those who conceive with assisted reproductive treatment methods
- Those who had any disease before pregnancy
- Those who have any uterine anomalies
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Those who had the first-trimester screening test between 11 and 14 weeks of pregnancy and are in the low-risk group
* Those with singleton pregnancy
* Those who did not conceive pregnancy with assisted reproductive treatment methods
* Those who do not have any pregestational diseases
* Those who do not have any uterine anomalies
Exclusion Criteria:
* Smokers
* Those who are in the high-risk group with the first trimester screening test
* Those with multiple pregnancies
* Those who conceive with assisted reproductive treatment methods
* Those who had any disease before pregnancy
* Those who have any uterine anomalies
Treatments Being Tested
DIAGNOSTIC_TEST
first trimester serum diagnostic test
First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
Locations (1)
Ümraniye Eğitim ve Araştırma Hastanesi
Istanbul, Ümraniye, Turkey (Türkiye)